MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
MANNKIND CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.09+0.05 (+1.64%)
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
MANNKIND CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | $71.58M | $55.92M | $75.78M | $48.27M | $44.68M | $47.79M | $45.61M | $42.96M | $46.76M | $43.23M | $37.32M | $30.73M | 65.4% | +60.2% |
| Sale of product | $41.98M | $33.91M | $50.41M | $22.31M | $22.45M | $18.97M | $23.06M | $19.73M | $20.78M | $18.76M | $20.20M | $17.93M | 38.4% | +87.0% |
| Collaborations and services | $35.02M | $23.52M | $27.99M | $26.51M | $22.85M | $29.38M | $26.71M | $23.27M | $26.01M | $24.85M | $17.25M | $13.11M | 32.0% | +53.3% |
| Royalties | $32.37M | $32.75M | $33.56M | $33.32M | $31.23M | $30.01M | $27.01M | $27.08M | $25.59M | $22.65M | $21.03M | $20.22M | 29.6% | +3.7% |
| Services | $5.42M | $1.50M | $2.61M | $537.00K | $621.00K | $558.00K | $4.16M | $37.00K | $36.00K | $384.00K | $121.00K | $308.00K | 5.0% | +773.3% |
| Product Sales | – | – | – | – | – | – | – | – | – | – | – | $30.73M | – | – |
| Manufacturing Services | – | $2.40M | $400.00K | $0 | $900.00K | $300.00K | $5.40M | $300.00K | $1.00M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Mannkind's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.